The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00763256 |
|
Recruitment Status :
Completed
First Posted : September 30, 2008
Results First Posted : April 2, 2012
Last Update Posted : July 28, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Periodontal Disease | Drug: Triclosan, Fluoride Drug: Fluoride | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 33 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics |
| Study Start Date : | May 2006 |
| Actual Primary Completion Date : | August 2009 |
| Actual Study Completion Date : | August 2009 |
| Arm | Intervention/treatment |
|---|---|
| Active Comparator: A |
Drug: Triclosan, Fluoride
subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
Other Name: triclosan/fluoride/copolymer toothpaste |
| Placebo Comparator: B |
Drug: Fluoride
subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
Other Name: current marketed fluoride only toothpaste |
- HbA1c Levels in Blood [ Time Frame: 12 months ]Glycated hemoglobin (HbA1c) is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. In this study, blood is taken from each subject and HbA1c levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS).
- High Sensitivity CRP (C-Reactive Protein) [ Time Frame: 12 months ]CRP is a protein found in the blood and is a marker for inflammation in the body. Inflammation plays a role in the initiation and progression of cardiovascular disease. Blood is taken from each subject and CRP levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS).
- C-Peptide [ Time Frame: 12 months ]C-Peptide levels in blood indicate whether or not a person is producing insulin. This peptide is usually found in equal levels to insulin. C-peptide levels measured as a means of distinguishing type 1 diabetes and type 2 diabetes. Blood is taken from each subject and C-Peptide levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS).
- Gingivitis Score (GI) [ Time Frame: 12 months ]
Units on a scale 0 to 3 (0 = no inflammation,
1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding)
- P. Gingivalis [ Time Frame: 12 months ]Subgingival plaque samples were collected from all interproximal (mesial) sites and pooled prior to assessment. The samples will be analysed for the presence of P. gingivalis, using real time PCR to quantitate the numbers of bacteria. P. gingivalis is a non-motile, gram negative, anaerobic, pathogenic bacteria. It is linked to periodontal disease and causes collagen degradation.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Poor glycaemic control as evidenced by an HbA1c of >6.0% for the past 12 months
- Aged 18 to 75 years
- Able to give informed consent
- Minimum of 12 teeth
- Chronic periodontitis as indicated by periodontal probing depths >5mm on at least 6 teeth
Exclusion Criteria:
- Pregnancy
- Gross dental caries
- Prosthetic heart valves, a history of infective endocarditis or any other condition requiring antibiotic cover for dental treatment (rheumatic fever, mitral valve prolapse with regurgitation)
- Anticoagulant therapy (excluding asprin)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00763256
| Australia | |
| Logan Hospital Oral Health Clinic | |
| Queensland, Australia | |
| Principal Investigator: | Gregory Seymour, BDS | University of Otago |
| Responsible Party: | Colgate Palmolive |
| ClinicalTrials.gov Identifier: | NCT00763256 |
| Other Study ID Numbers: |
2004000841/2004/201 |
| First Posted: | September 30, 2008 Key Record Dates |
| Results First Posted: | April 2, 2012 |
| Last Update Posted: | July 28, 2015 |
| Last Verified: | July 2015 |
|
Periodontal Diseases Mouth Diseases Stomatognathic Diseases Triclosan Fluorides Cariostatic Agents Protective Agents Physiological Effects of Drugs |
Anti-Infective Agents, Local Anti-Infective Agents Fatty Acid Synthesis Inhibitors Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents |

